NCT00056082View on ClinicalTrials.gov

Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

celecoxib

Celecoxib daily for 12 months

Trial Locations (3)

60611

Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital, Chicago

73104

Oklahoma University Medical Center, Oklahoma City

66160-7820

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Kansas Medical Center

OTHER

NCT00056082 - Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women | Biotech Hunter | Biotech Hunter